SOUTH
SAN FRANCISCO, Calif., Dec. 3, 2023
/PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a
precision medicine oncology company committed to the discovery and
development of targeted therapeutics, announced agenda topics for
its Investor R&D Day. The webcast event will be hosted by
IDEAYA on Monday, December 4, 2023 at
8:00 am to 9:30 am ET.
The presentations by IDEAYA management and key opinion leaders
will showcase scientific insights and clinical development
opportunities across IDEAYA's synthetic lethality pipeline,
including IDE397 (MAT2A) in Phase 2, IDE161 (PARG) in Phase 1,
GSK101/IDE705 (Pol Theta Helicase) in Phase 1, and the Werner
Helicase program for which an IND submission is planned for 2024.
In addition, IDEAYA will highlight its next generation initiatives
for MTAP-deletion, that include a wholly-owned program where a
development candidate nomination is targeted in 2024 and multiple
first-in-class clinical combination opportunities. The IDEAYA
Investor R&D Day Webcast agenda will be the following:
Agenda Topics
- The Synthetic Lethality Paradigm
- IDEAYA Vision, Strategy and Pipeline (Yujiro S. Hata, CEO)
- Computational Drug Discovery
- Overview of Current Approaches at IDEAYA (Mike White, CSO)
- IDE161 Clinical Data and Program Updates (Timothy Yap, MD Anderson)
- Emerging Therapeutic Opportunities for MTAP-deletion
- IDEAYA's Multiple-Pronged Strategy (Mike White, CSO; Darrin
Beaupre, CMO)
- IDEAYA and GSK Partnership
- Pol Theta Helicase and Werner Helicase Programs (Ramon Kemp, GSK)
Key Opinion Leader Presenters
- Timothy Yap, M.D., Associate
Professor, Department for Investigational Cancer Therapeutics and
Department of Thoracic/Head and Neck Medical Oncology, Medical
Director, Institute for Applied Cancer Science, Associate Director
of Translational Research, Institute for Personalized Cancer
Therapy, M.D. Anderson Cancer Center
- Ramon Kemp, Ph.D., Vice
President, Head, Oncology EDL, Interim Head, Oncology MDL, GSK
Investor R&D Day Webcast Presentation and Registration
Information
IDEAYA's Investor R&D Day webcast presentation will be
available on the company's website, at its Investor Relations
portal (https://ir.ideayabio.com/) in advance of the investor
webcast presentation at approximately 6:00
am ET.
Registration is available at https://ir.ideayabio.com/events or
https://lifescievents.com/event/ideaya/.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the
discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's approach
integrates capabilities in identifying and validating translational
biomarkers with drug discovery to select patient populations most
likely to benefit from its targeted therapies. IDEAYA is applying
its early research and drug discovery capabilities to synthetic
lethality – which represents an emerging class of precision
medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, (i) statements related to
participation in, presentation at, and/or content of certain
investor relations events, (ii) timing of an IND submission for the
Werner Helicase program, and (iii) timing of development candidate
nomination for next generation initiatives. IDEAYA undertakes no
obligation to update or revise any forward-looking statements. For
a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to the
business of IDEAYA in general, see IDEAYA's Quarterly Report on
Form 10-Q filed on November 7, 2023
and any current and periodic reports filed with the U.S. Securities
and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-announces-agenda-for-investor-rd-day-webcast-on-december-4-2023-302003703.html
SOURCE IDEAYA Biosciences, Inc.